SAN FRANCISCO — Hims & Hers, a leading platform for personalized health and wellness, has launched its Compounded Semaglutide Pill for weight loss, further expanding access to individualized treatment options for millions of Americans. As part of a 5‑month plan, introductory pricing begins at $49 for the first month.
The new once‑daily pill contains the same active ingredient as Wegovy and is designed for patients who prefer to avoid injections or who may benefit from more flexible dosing to help manage side effects. The specialized formulation is engineered to protect the medication through digestion and support effective absorption, giving healthcare providers an additional option to tailor plans to their patients’ unique needs.
“At Hims & Hers, we believe the best outcomes start with choice,” Dr. Craig Primark at the Scottsdale Weight Loss Center wrote on the Hims & Hers website. “By offering branded, generic, and compounded treatments side‑by‑side, we empower providers to develop personalized care plans that meet each patient where they are. Our new Compounded Semaglutide Pill represents an important step forward in expanding access to high‑quality weight‑loss care.”
Commitment to Safety and Quality
Safety remains the company’s highest priority. All compounded medications offered through the Hims & Hers platform adhere to rigorous clinical standards and comply with all federal and state compounding regulations. All active pharmaceutical ingredients (APIs) are sourced exclusively from FDA‑registered facilities.
Built on Eight Years of Infrastructure Investment
The introduction of the Compounded Semaglutide Pill is made possible by eight years of sustained investment in the company’s pharmaceutical and fulfillment infrastructure. In 2025, Hims & Hers doubled its facility footprint to more than one million square feet, adding state‑of‑the‑art pharmacy capabilities, lab testing services, and dedicated R&D space. This scale supports the rapid development and delivery of next‑generation personalized treatments across the platform.
“Our infrastructure allows providers to seamlessly personalize care across branded, generic, and compounded options,” said the company on its website. “And as we continue to grow, we look forward to partnering with manufacturers of leading branded therapies to bring even more choice to our customers,” wrote Primark.
Expanding Access to Better Outcomes
Hims & Hers’ mission is rooted in a simple goal: better outcomes through better access. By broadening its weight‑loss treatment portfolio to include the Compounded Semaglutide Pill, the company continues its commitment to helping customers achieve improved energy, better sleep, lower blood sugar, enhanced mood, and sustained weight‑loss success.
“As we expand personalized weight‑loss care for millions of Americans, we remain focused on empowering individuals to take control of their health and live better with confidence,” he added.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
